MEDI6012

BIOLOGICAL3 trials

Sponsors

MedImmune LLC, Columbia University

Conditions

Cardiovascular DiseasesCoronary Artery DiseaseST Elevation Myocardial Infarction

Phase 2

To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease

CompletedNCT02601560

MedImmune LLCCoronary Artery Disease

Start: 2015-12-03End: 2016-11-03Updated: 2018-03-19

A Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction

CompletedNCT03578809

MedImmune LLCST Elevation Myocardial Infarction

Start: 2018-06-05End: 2021-01-18Updated: 2022-02-09

Study to Evaluate the Effects of MEDI6012 on Apolipoprotein B100 Metabolism

TerminatedNCT03773172

Columbia UniversityCardiovascular Diseases

Start: 2019-01-31End: 2020-08-31Updated: 2024-11-12

Related Papers

Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segment–Elevation Myocardial Infarction: Results of REAL-TIMI 63B

Circulation2022-09-1920 citations

LCAT-trial-24 weeks: Protocol for a clinical study to evaluate the safety of regenerative medicine and gene therapy by the autologous transplantation of human lecithin:cholesterol acyltransferase gene-transduced human pre-adipocytes

Contemporary Clinical Trials Communications2022-06-091 citations

MEDI6012: Recombinant Human Lecithin Cholesterol Acyltransferase, High‐Density Lipoprotein, and Low‐Density Lipoprotein Receptor–Mediated Reverse Cholesterol Transport

Journal of the American Heart Association2021-06-1427 citations